Renal denervation for blood pressure in people on hemodialysis
Tests renal denervation, a device procedure, in adults with resistant high blood pressure on dialysis.
Plain-language title generated from the registry record
Registry title: Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis
Key facts
- Where
- Erlangen, GermanySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06556407, who can take part
Where in Germany
- Friedrich Alexander University Erlangen Nuremberg, Department of Nephrology and HypertensionErlangen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Erlangen-Nürnberg Medical School
- Trial code
- NCT06556407
- Record updated
- 26 September 2025
- Original description
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.Read full original descriptionShow less
Effect of Renal Denervation on Blood Pressure in Patients With Treatment Resistant Hypertension, End-stage Chronic Kidney Disease and Hemodialysis
The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.
Inclusion: Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140/ and/ or ≥ 90 mmHg and ambulatory blood pressure ≥ 130/ and/or ≥ 80 mmHg; end-stage renal disease on chronic hemodialysis; Stable hemodialysis regime for at least 3 months based on the decision of the treating physician; Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks; Individual is ≥ 18 years of age, male and female patients are included.
Exclusion: Prior renal denervation procedure; Anatomic or functional solitary kidney, kidney transplantation; Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements; Endocrine hypertension other than obstructive sleep apnea; Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit; Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months; Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence); Episodes of sustained systolic and/or diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient; Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement; Subject is pregnant, nursing, or intends to become pregnant; Enrollment in another interventional research protocol.